Alexion Pharmaceuticals ALXN today announced the
initiation of dosing in a single, multinational, placebo-controlled
clinical trial to evaluate the efficacy and safety of eculizumab (Soliris®)
for the prevention of delayed graft function (DGF) after kidney
transplantation in adult patients who are at increased risk of DGF. DGF
is an early and serious complication of organ transplantation that
affects approximately 25 percent,1 and possibly up to 50
percent,2 of deceased-donor kidney transplant cases, and is
characterized by the failure of a transplanted organ to function
normally immediately following transplantation. Patients experiencing
DGF after a kidney transplant require dialysis in order to survive.3-5
Worldwide, there is an unmet medical need for a highly innovative
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in